FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022770843> ?p ?o ?g. }

• W2022770843 abstract "Signaling pathways that converge on two different transcription factor complexes, NFkappaB and AP-1, have been identified in estrogen receptor (ER)-positive breast cancers resistant to the antiestrogen, tamoxifen.Two cell line models of tamoxifen-resistant ER-positive breast cancer, MCF7/HER2 and BT474, showing increased AP-1 and NFkappaB DNA-binding and transcriptional activities, were studied to compare tamoxifen effects on NFkappaB and AP-1 regulated reporter genes relative to tamoxifen-sensitive MCF7 cells. The model cell lines were treated with the IKK inhibitor parthenolide (PA) or the proteasome inhibitor bortezomib (PS341), alone and in combination with tamoxifen. Expression microarray data available from 54 UCSF node-negative ER-positive breast cancer cases with known clinical outcome were used to search for potential genes signifying upregulated NFkappaB and AP-1 transcriptional activity in association with tamoxifen resistance. The association of these genes with patient outcome was further evaluated using node-negative ER-positive breast cancer cases identified from three other published data sets (Rotterdam, n = 209; Amsterdam, n = 68; Basel, n = 108), each having different patient age and adjuvant tamoxifen treatment characteristics.Doses of parthenolide and bortezomib capable of sensitizing the two endocrine resistant breast cancer models to tamoxifen were capable of suppressing NFkappaB and AP-1 regulated gene expression in combination with tamoxifen and also increased ER recruitment of the transcriptional co-repressor, NCoR. Transcript profiles from the UCSF breast cancer cases revealed three NFkappaB and AP-1 upregulated genes--cyclin D1, uPA and VEGF--capable of dichotomizing node-negative ER-positive cases into early and late relapsing subsets despite adjuvant tamoxfien therapy and most prognostic for younger age cases. Across the four independent sets of node-negative ER-positive breast cancer cases (UCSF, Rotterdam, Amsterdam, Basel), high expression of all three NFkappaB and AP-1 upregulated genes was associated with earliest metastatic relapse.Altogether, these findings implicate increased NFkappaB and AP-1 transcriptional responses with tamoxifen resistant breast cancer and early metastatic relapse, especially in younger patients. These findings also suggest that agents capable of preventing NFkappaB and AP-1 gene activation may prove useful in restoring the endocrine responsiveness of such high-risk ER-positive breast cancers." @default.
• W2022770843 created "2016-06-24" @default.
• W2022770843 creator A5013069844 @default.
• W2022770843 creator A5027187873 @default.
• W2022770843 creator A5028899187 @default.
• W2022770843 creator A5031592069 @default.
• W2022770843 creator A5045186236 @default.
• W2022770843 creator A5059617881 @default.
• W2022770843 creator A5062190609 @default.
• W2022770843 creator A5069464048 @default.
• W2022770843 creator A5071113287 @default.
• W2022770843 date "2007-04-03" @default.
• W2022770843 modified "2023-10-06" @default.
• W2022770843 title "Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer" @default.
• W2022770843 cites W1736447480 @default.
• W2022770843 cites W1827067753 @default.
• W2022770843 cites W1889063846 @default.
• W2022770843 cites W1889928106 @default.
• W2022770843 cites W1898692666 @default.
• W2022770843 cites W1919901534 @default.
• W2022770843 cites W1976382352 @default.
• W2022770843 cites W1997006452 @default.
• W2022770843 cites W2016569614 @default.
• W2022770843 cites W2019933602 @default.
• W2022770843 cites W2031547755 @default.
• W2022770843 cites W2040025789 @default.
• W2022770843 cites W2040449012 @default.
• W2022770843 cites W2044846423 @default.
• W2022770843 cites W2052306492 @default.
• W2022770843 cites W2053252897 @default.
• W2022770843 cites W2062713892 @default.
• W2022770843 cites W2068872058 @default.
• W2022770843 cites W2075172358 @default.
• W2022770843 cites W2076931659 @default.
• W2022770843 cites W2078095448 @default.
• W2022770843 cites W2078168707 @default.
• W2022770843 cites W2085949544 @default.
• W2022770843 cites W2093350076 @default.
• W2022770843 cites W2096205264 @default.
• W2022770843 cites W2100907853 @default.
• W2022770843 cites W2106792841 @default.
• W2022770843 cites W2107696861 @default.
• W2022770843 cites W2108542713 @default.
• W2022770843 cites W2112018984 @default.
• W2022770843 cites W2114108429 @default.
• W2022770843 cites W2128985829 @default.
• W2022770843 cites W2131994307 @default.
• W2022770843 cites W2141232624 @default.
• W2022770843 cites W2143033696 @default.
• W2022770843 cites W2143185770 @default.
• W2022770843 cites W2147096476 @default.
• W2022770843 cites W2150019121 @default.
• W2022770843 cites W2150081723 @default.
• W2022770843 cites W2151808231 @default.
• W2022770843 cites W2154762061 @default.
• W2022770843 cites W2155458526 @default.
• W2022770843 cites W2163563958 @default.
• W2022770843 cites W2165235893 @default.
• W2022770843 cites W2168470728 @default.
• W2022770843 cites W27614701 @default.
• W2022770843 cites W306915739 @default.
• W2022770843 cites W4245024447 @default.
• W2022770843 cites W53823551 @default.
• W2022770843 doi "https://doi.org/10.1186/1471-2407-7-59" @default.
• W2022770843 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1852565" @default.
• W2022770843 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17407600" @default.
• W2022770843 hasPublicationYear "2007" @default.
• W2022770843 type Work @default.
• W2022770843 sameAs 2022770843 @default.
• W2022770843 citedByCount "192" @default.
• W2022770843 countsByYear W20227708432012 @default.
• W2022770843 countsByYear W20227708432013 @default.
• W2022770843 countsByYear W20227708432014 @default.
• W2022770843 countsByYear W20227708432015 @default.
• W2022770843 countsByYear W20227708432016 @default.
• W2022770843 countsByYear W20227708432017 @default.
• W2022770843 countsByYear W20227708432018 @default.
• W2022770843 countsByYear W20227708432019 @default.
• W2022770843 countsByYear W20227708432020 @default.
• W2022770843 countsByYear W20227708432021 @default.
• W2022770843 countsByYear W20227708432022 @default.
• W2022770843 countsByYear W20227708432023 @default.
• W2022770843 crossrefType "journal-article" @default.
• W2022770843 hasAuthorship W2022770843A5013069844 @default.
• W2022770843 hasAuthorship W2022770843A5027187873 @default.
• W2022770843 hasAuthorship W2022770843A5028899187 @default.
• W2022770843 hasAuthorship W2022770843A5031592069 @default.
• W2022770843 hasAuthorship W2022770843A5045186236 @default.
• W2022770843 hasAuthorship W2022770843A5059617881 @default.
• W2022770843 hasAuthorship W2022770843A5062190609 @default.
• W2022770843 hasAuthorship W2022770843A5069464048 @default.
• W2022770843 hasAuthorship W2022770843A5071113287 @default.
• W2022770843 hasBestOaLocation W20227708431 @default.
• W2022770843 hasConcept C104317684 @default.
• W2022770843 hasConcept C121608353 @default.
• W2022770843 hasConcept C126322002 @default.
• W2022770843 hasConcept C127561419 @default.
• W2022770843 hasConcept C143998085 @default.
• W2022770843 hasConcept C2776067312 @default.
• W2022770843 hasConcept C2776364478 @default.

• next